-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Obtains Drug Production Registration Approval for Prucalopride Succinate Tablets
Category:
发布时间：2020-07-27
【概要描述】
Recently, Shijiazhuang Sihua Pharmaceutical Co., Ltd. obtained drug registration certificates from the National Medical Products Administration for prucalopride succinate tablets (1 mg and 2 mg).
Recently, Shijiazhuang Sihua Pharmaceutical Co., Ltd. obtained drug registration certificates from the National Medical Products Administration for prucalopride succinate tablets (1 mg and 2 mg).
The succinate prucalopride tablets (1 mg and 2 mg) approved this time were submitted under Category 4 of the Chemical Drug Registration Classification and, upon approval, will be deemed to have passed the consistency evaluation. Shijiazhuang Sihua Pharmaceutical is one of only three domestic companies that have already passed the consistency evaluation for this product.
According to the introduction, prucalopride succinate tablets are primarily used to treat symptoms of chronic constipation.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091